Latest stomach cancer Stories

Broccoli sprouts effectively control Helicobacter pylori bacteria, known to be a leading cause of stomach ulcers and stomach cancer, researchers found.Researchers studied 50 people in Japan and found that eating 2.5 ounces of broccoli sprouts each day for two months could suppress the bacteria.Broccoli contains a phytochemical called sulforaphane, which has an antibiotic affect that has been known for almost two decades, researchers said in the report in Cancer Prevention Research, a journal...

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate. TNM staging system is used worldwide to predict prognosis and direct therapeutic decisions of patients with GC. However, the prognoses of patients with stage 2 and 3 GC are more heterogeneous and less predictable by staging criteria. Therefore, finding molecular markers that are able to predict the potential of tumor recurrence and prognosis of patients is extremely important for...

A 7-year-old girl New York girl is doing well after having six of her organs removed in an effort to remove a cancerous tumor, doctors said. She was scheduled to be released from the hospital Tuesday, a month after having undergone the risky, yet apparently successful, procedure. The surgery, believed to be the first in a child and the second in the world, involved the removal and partial re-implantation of six organs. The 23-hour procedure, which began Feb. 6, was lead by Dr. Tomoaki Kato...

A new British study finds that taking ibuprofen or aspirin, even in very low doses, might protect against stomach cancer.The research found that those who had taken aspirin at least once during the previous year reduced by 36 percent their chances of developing cancer in the middle or lower parts of the stomach, when compared with those who had taken no aspirin.Taking similar doses of a non-steroidal anti-inflammatory drug (NSAID), such as ibuprofen, reduced the chances of developing stomach...

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX), announced today that it has completed patient enrollment in its bioequivalence study of ANX-514 (docetaxel emulsion for injection). The Company is on track to announce results from this study in the second quarter of 2009. ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate,...

DURHAM, N.C., Feb. 2 /PRNewswire/ -- Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures portfolio company, announced today that it has completed its acquisition of all the technology and intellectual property for a suite of products that enhance the immune system for application in three gastrointestinal cancers. Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire products developed to inhibit the hormone, gastrin, for an undisclosed purchase...

First human trial demonstrates feasibility and safety of MAG techniqueA prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a feasible and safe method in humans. Endoscopic submucosal dissection (ESD) is useful in the en bloc removal (in a single large piece) of large gastric lesions because it reduces the risk of a local recurrence caused by removing the lesions piecemeal (in multiple small...

Two non-surgical, non-pharmacological treatments for gastroesophageal reflux disease both appear effective in reducing medication use, U.S. researchers say. GERD -- a condition in which acid from the stomach backs up into the esophagus -- is typically treated first with medications such as proton pump inhibitors. However, it may be difficult for patients to comply with or afford long-term drug therapy, and GERD returns more than 80 percent of the time when medication is discontinued. One...

Research published in Journal of the American College of Surgeons finds survival rate of nearly 80 percentNew research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years.GIST is a type of cancer arising from special cells in the wall of the...

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy - Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients - Gastric cancer is the second leading cause of cancer death worldwide with the majority of new cases occurring in East Asia EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Data released today show RAD001 (also known as everolimus;...